Equity and quality use of medicines in people who present to the Psychiatric Alcohol and Non‐Prescription Drug Assessment Unit
British Journal of Clinical Pharmacology · 2025
DOI: 10.1002/bcp.70366 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, 2025. Verfasst von Jana Stojanova und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology and Toxicology, St Vincent's Hospital, Sydney, Australia. Hauptthemen laut MEDLINE: Polypharmacy, Inappropriate Prescribing, Practice Patterns, Physicians', Nonprescription Drugs. Die Arbeit nennt 30 Literaturangaben.
Abstract (Originalsprache)
Aim
To evaluate quality use of medicines (QUM) in patients admitted to the Psychiatric Alcohol and Non‐Prescription Drug Assessment (PANDA) Unit through analysis of polypharmacy risk, prescribing safety indicators and national QUM indicators.
Methods
Retrospective review of electronic medical records for 787 patients (1245 episodes) admitted to PANDA Unit, St Vincent's Hospital Sydney, November 2020–December 2021. We assessed polypharmacy risk using NSW Therapeutic Advisory Group's Inappropriate Polypharmacy Risk Assessment Tool, evaluated nine prescribing safety indicators (PSIs) and assessed four national quality use of medicines indicators (NQUMIs) in a randomly selected subset of 103 patients.
Results
Mean age was 40.2 years; 67.2% were male. Alcohol‐related diagnoses comprised 32.1% of presentations. Medium‐risk (43.5%) and high‐risk (37.2%) polypharmacy were prevalent, largely reflecting protocol‐driven prescribing for acute presentations. Co‐prescription of QT‐prolonging drugs with antipsychotics affected 17.2% of patients, with 64.7% associated with rapid sedation protocols; only one case of potential QT prolongation was documented. Major gaps were identified in medication reconciliation (40.8% had documented medication history) and discharge documentation (13.1% of discharge summaries contained complete medication information). Patients experiencing homelessness demonstrated poorer outcomes across all QUM indicators, with no discharge summaries meeting quality standards.
Conclusion
While PANDA demonstrated appropriate protocol‐driven prescribing for acute psychiatric presentations, substantial gaps in medication reconciliation and discharge communication highlight challenges in care transitions for priority populations. Standard polypharmacy and prescribing safety indicators may require adaptation for acute psychiatric settings to distinguish appropriate acute prescribing from potentially inappropriate practices.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacology and Toxicology, St Vincent's Hospital, Sydney, Australia.
- School of Clinical Medicine, St Vincent's Healthcare Clinical Campus, Faculty of Medicine and Health, UNSW Sydney, Sydney, Australia.
- School of Medical Sciences, Faculty of Medicine and Health, UNSW Sydney, Sydney, Australia.
- Pharmacy Department, St. Vincent's Hospital, Sydney, Australia.
ORCID-Profile: Jana Stojanova, Jonathan Brett, Jane Ellen Carland, Richard Osborne Day, Bridin Murnion
Zitieren
APA
Stojanova, J., Choy, E. B. K., Brett, J., Carland, J. E., Malek, N., Day, R. O., & Murnion, B. (2025). Equity and quality use of medicines in people who present to the Psychiatric Alcohol and Non‐Prescription Drug Assessment Unit. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70366
Vancouver
Stojanova J, Choy EBK, Brett J, Carland JE, Malek N, Day RO, et al. Equity and quality use of medicines in people who present to the Psychiatric Alcohol and Non‐Prescription Drug Assessment Unit. British Journal of Clinical Pharmacology. 2025. doi:10.1002/bcp.70366
BibTeX
@article{Stojanova2025,
author = {Stojanova, Jana and Choy, Elysse Bo Kwan and Brett, Jonathan and Carland, Jane Ellen and Malek, Nader and Day, Richard Osborne and Murnion, Bridin},
title = {Equity and quality use of medicines in people who present to the Psychiatric Alcohol and Non‐Prescription Drug Assessment Unit},
journal = {British Journal of Clinical Pharmacology},
year = {2025},
doi = {10.1002/bcp.70366}
}
EUVIMED